Smaller companies are seen taking the driver’s seat in deal-making during 2022 while the traditional deal initiators - large biopharma companies - are expected to slow down, a new survey shows.
Overall, deal flow sentiment for 2022 suggests an increase over the previous year, though not to the levels seen for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
